Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.
about
Cancer Metabolism and Drug ResistanceTargeting glycogen metabolism in bladder cancerMolecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder CancerUse of Accelerator Mass Spectrometry in Human Health and Molecular ToxicologyThe miR-193a-3p-regulated ING5 gene activates the DNA damage response pathway and inhibits multi-chemoresistance in bladder cancer.Clinical potential of gene mutations in lung cancer.DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing.A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.Diagnostic Microdosing Approach to Study Gemcitabine Resistance.A Quinone-Containing Compound Enhances Camptothecin-Induced Apoptosis of Lung Cancer Through Modulating Endogenous ROS and ERK Signaling.Alternative therapies in patients with non-muscle invasive bladder cancer.Bioanalysis annual round-up: the bioanalysis editorial team is delighted to welcome you to this mid-year round-up.Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry.The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials.
P2860
Q26782042-489C17E2-EEAA-4635-98FA-EDAAFFE3081EQ27025144-8E921041-0072-49FA-8CA7-C91039CCBEC6Q28552735-685969E9-AF20-4317-B01A-64779B6AA63AQ28818313-F42F06D5-D450-46A9-9FB3-6A1A5A75FB3CQ35832954-8431FB01-D59F-4719-A1B4-65D0C91C1D66Q36316009-FE91064E-7A4B-47B6-8426-6F979DF7124BQ37736567-75E156CD-89FF-47C5-8CD5-861228B6DCD5Q38186660-34F484B6-3E49-46E1-9A58-FC039E45E767Q38706298-FC8B5A5E-CA99-4066-907D-5CBDA02AD7E1Q38728212-FF04AE80-2783-4E62-94D2-6E7E85BA4967Q38744400-89FAFE50-5C9E-47A2-AF5A-275303FEFB71Q46484915-4553C502-DD7B-4677-8384-AA9B0D2FA1F1Q47114392-7E478874-AF15-455D-8790-546891BD56A0Q48165229-A80DFE0C-86FE-40F0-B707-6B5B64FF623DQ54999095-C039AA64-F553-429D-8DED-6C248A43CFEBQ55409671-FDCC3498-AD95-4582-B5D5-D935AF2CCFC7
P2860
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Personalized medicine for targ ...... py of lung and bladder cancer.
@ast
Personalized medicine for targ ...... py of lung and bladder cancer.
@en
type
label
Personalized medicine for targ ...... py of lung and bladder cancer.
@ast
Personalized medicine for targ ...... py of lung and bladder cancer.
@en
prefLabel
Personalized medicine for targ ...... py of lung and bladder cancer.
@ast
Personalized medicine for targ ...... py of lung and bladder cancer.
@en
P2093
P2860
P356
P1433
P1476
Personalized medicine for targ ...... py of lung and bladder cancer.
@en
P2093
Chong-xian Pan
George D Cimino
Paul T Henderson
P2860
P304
P356
10.4155/BIO.12.325
P577
2013-02-01T00:00:00Z